Ann: ADVENT-AML Phase 1B clinical trial update, page-88

Thanks, I had missed that statement.



Re this table - I can't find any data reported from the first 6 patients in the dose escalation cohort. Has this been released? 6 patients with two planned levels of dose escalation - assuming 3 patients in each? Would that not imply 6 patients received/receiving the optimal dose regime?

It would be nice if CHM included more data in their announcements.

As you and Shellbell mention, there is at least one of these patients that has responded prior to the completion of treatment. It's looking increasingly likely that this news was published with the sole intention of raising more cash and with no way of identifying if these responses were any way attributable to NK Cells.